Library

ANG1005

Share on Facebook Share on Twitter Email
Wikipedia on Answers.com:

ANG1005

Top
Home > Library > Miscellaneous > Wikipedia
Wiki letter w.svg
 This article is an orphan, as few or no other articles link to it. Please introduce links to this page from related articles; suggestions may be available. (December 2008)

ANG1005 is a drug candidate engineered to cross the blood brain barrier to deliver chemotherapy for the treatment of glioma.

It is made up of one molecule of a peptide called Angiopep-2 joined together with three molecules of Paclitaxel, a taxane-chemotherapy drug. It reduced tumour growth in mice and rats with glioblastoma tumors.[1][2][3]

It targets lipoprotein receptor-related protein (LRP-1) which is upregulated in some cancers.[4]

In 2008 two Phase-I clinical trials of ANG1005 were started ; one in patients with advanced cancer and brain metastases,[5] and another in patients with recurrent malignant glioma.[6] Favourable initial tolerability results in brain cancer were reported in March 2009.[7] and more in October 2009 and updated in June 2010.[4]

References

  1. ^ Régina A, Demeule M, Ché C, Lavallée I, Poirier J, Gabathuler R, Béliveau R, Castaigne JP (2008). "Antitumour activity of ANG1005, a conjugate between paclitaxel and the new brain delivery vector Angiopep-2". Br J Pharmacol 155 (2): 185–197. doi:10.1038/bjp.2008.260. PMC 2538693. PMID 18574456. http://www.nature.com/bjp/journal/v155/n2/abs/bjp2008260a.html. 
  2. ^ Thomas FC, Taskar K, Rudraraju V, Goda S, Thorsheim HR, Gaasch JA, Mittapalli RK, Palmieri D, Steeg PS, Lockman PR, Smith QR (2009 Nov). "Uptake of ANG1005, a Novel Paclitaxel Derivative, Through the Blood-Brain Barrier into Brain and Experimental Brain Metastases of Breast Cancer". Pharm Res 26 (11): 2486–94. doi:10.1007/s11095-009-9964-5. PMC 2896053. PMID 19774344. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2896053. 
  3. ^ Patel MM, Goyal BR, Bhadada SV, Bhatt JS, Amin AF (2009). "Getting into the brain: approaches to enhance brain drug delivery". CNS Drugs 23 (1): 35–58. doi:10.2165/0023210-200923010-00003. PMID 19062774. 
  4. ^ a b "Angiochem Presents Complete Phase 1 /2 Clinical Data for ANG1005: Further Demonstrating Benefits of Targeting LRP-1 Pathway in Cancer". Pharmalive.com. http://www.pharmalive.com/News/index.cfm?articleid=709562.  (paid subscription required)[unreliable medical source?][verification needed]
  5. ^ "A Phase 1, Open-Label, Dose Escalation Study of ANG1005 in Patients With Advanced Solid Tumors and Metastatic Brain Cancer". 3 June 2010. http://clinicaltrials.gov/ct2/show/NCT00539383?spons=%22Angiochem+Inc%22&spons_ex=Y&rank=2. Retrieved 16 August 2010. 
  6. ^ "angiochems-ang1005-demonstrates-preliminary-clinical-safety-and-tolerability-in-brain-cancers" (Press release). CheckOrphan.com. http://www.checkorphan.org/grid/news/research/angiochems-ang1005-demonstrates-preliminary-clinical-safety-and-tolerability-in-brain-cancers. Retrieved 16 August 2010. [unreliable medical source?]
  7. ^ "AngioChem's ANG1005 Shows Promise In The Treatment Of Brain Cancers". 23 October 2008. http://www.medicalnewstoday.com/articles/143129.php. 

External links


Stub icon This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)

Post a question - any question - to the WikiAnswers community:

Copyrights:

Cite
Wikipedia on Answers.com This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article ANG1005. Read more

Featured guides

» More

Mentioned in

Paclitaxel